Clover, Chengda IPOs Add To $1.2bn Raised By Chinese Bioventures

The listings of two vaccine manufacturers and fundraisings by seven other biopharma ventures generate around $1.2bn in new financing for Chinese companies focusing on a broad variety of therapeutic areas and indicating continued investor interest.